Business Context and Reporting Period
Company: DENTSPLY SIRONA Inc.
Filing Type: Form 8-K (Current Report)
Date: October 24, 2024
Reporting Period: Third quarter ended September 30, 2024 (preliminary results).
Key Financial Metrics
- Net Sales (Q3 2024): Approximately $951 million (preliminary).
- Adjusted EPS (Q3 2024): Between $0.49 and $0.51 (preliminary).
- Goodwill Impairment: Expected non-cash charge of $450 million to $550 million (net of tax) related to Orthodontic Aligner Solutions and Implant & Prosthetic Solutions reporting units.
- Segment Performance:
- Essential Dental Solutions: Year-over-year growth (partially offset by timing shifts).
- Orthodontic and Implant Solutions: Declines.
- Connected Technology Solutions: Declines.
- Wellspect Healthcare: Approximately flat due to distributor timing.
- Byte Business Impact: Represents approximately 5% of annual revenue.
Material Changes and Operational Events
- Voluntary Suspension: The Company is suspending the sale, marketing, shipment, and processing of new orders for its Byte Aligner System and Impression Kits as a precautionary measure following consultation with the FDA.
- Impairment Drivers:
- Orthodontic Aligner Solutions: Adverse impacts from state regulatory trends regarding direct-to-consumer aligner business.
- Implant & Prosthetic Solutions: Weakened demand, competitive pricing pressures, global conflicts, and lower long-term volume expectations for lab materials.
- Timing Adjustments: Net sales and adjusted EPS were favorably impacted by approximately $20 million in distributor orders for Essential Dental Solutions shifted from Q4 to Q3.
Outlook, Risks, and Management Commentary
- Future Impairments: The Company may incur additional material impairments and write-offs regarding the Byte business as it assesses next steps.
- Regulatory Risks: Failure to resolve regulatory issues could lead to FDA actions including fines, injunctions, recalls, or suspension of production, which would materially adversely impact financial status.
- Guidance Update: The Company will provide an update to its 2024 full-year outlook during its earnings call scheduled for November 7, 2024.
- GAAP EPS: No forward-looking or preliminary estimates for GAAP adjusted EPS are provided due to the inability to reconcile adjusting items without unreasonable effort prior to quarter-end closing.
Investor Verification Checklist
- Verify the final Q3 2024 financial results and the exact goodwill impairment amount in the upcoming Form 10-Q.
- Monitor the status of the FDA review regarding Byte Aligner Systems and the timeline for potential resumption of sales.
- Assess the potential for additional write-offs beyond the initial $450-$550 million impairment range.
- Review the updated 2024 full-year guidance provided on the November 7, 2024 earnings call.
- Confirm the impact of the Byte suspension on the Orthodontic and Implant Solutions segment revenue for Q4 2024.